Skip to content

Clinical trials

Neoplasm Metastasis trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neoplasm Metastasis Clear all

3,585 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200024
200142
200245
200359
200470
200597
2006121
2007115
2008107
2009130
2010131
2011134
2012127
2013143
2014158
2015119
2016149
2017140
2018135
2019156
2020155
2021240
2022193
2023170
2024154
2025157
2026189

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed1,581
Terminated542
Recruiting517
Unknown status402
Active, not recruiting252
Withdrawn143
Not yet recruiting120
Suspended15
Enrolling by invitation5
No longer available3
Available3
Approved for marketing2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center127
National Cancer Institute (NCI)123
Eli Lilly and Company72
AstraZeneca53
Memorial Sloan Kettering Cancer Center51
Novartis Pharmaceuticals42
Pfizer41
H. Lee Moffitt Cancer Center and Research Institute33
Amgen29
University Health Network, Toronto29

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neoplasm Metastasis3,585
Neoplasms640
Breast Neoplasms547
Colorectal Neoplasms434
Carcinoma, Non-Small-Cell Lung344
Melanoma272
Recurrence254
Prostatic Neoplasms246
Lung Neoplasms243
Pancreatic Neoplasms221

Trials

Showing 76 to 100 of 3,585. Each trial links to its page on Pharma Observatory.

3,485 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.